Oncolytic virus (OV) therapy utilizes replication-competent viruses to kill cancer cells, leaving non-malignant ("normal") cells unharmed. The first correlative observations of tumor regression following viral infection were reported in the mid-1800s. 1 In the last 20 years, the development of new genetic techniques has allowed for an explosion of preclinical and clinical research with almost every major group of animal virus being tested for OV efficacy against most cancer types. There are currently at least three OVs approved for clinical use, including the U.S. Food and Drug Administration-approved 2 and
The European Commission-approved 3 talimogene laherparepvec (T-VEC; based on herpes simplex virus 1) for inoperable metastatic melanoma; Riga virus (RIGVIR; based on enteric cytopathic human orphan virus 7) for melanoma in Latvia, Georgia, and Armenia; 4 and Gendicine and Oncorine (both based on adenovirus type 5) for head and neck squamous cell carcinoma in China. 5 Rational OV development aims to generate ideal OVs that are: (1) highly attenuated in healthy tissues and safe in patients with weakened immune systems (oncoselectivity); (2) highly effective at infecting and killing cancer cells (oncotoxicity); (3) able to stimulate an adaptive immune response against cancer cells; and (4) resistant to premature clearance by the immune system during treatment.
Despite encouraging results, OV monotherapy based exclusively on virus replication-induced oncolysis often does not demonstrate all of these desired qualities, especially when tested against virus-resistant malignancies. Today's hurdles facing OV therapies remain the same as those described in early [6] [7] [8] and recent reviews. 9, 10 Several methods have been developed to increase the anti-cancer activities of OVs. Most commonly, OVs are engineered to express an exogenous transgene with anti-tumor activity and/or combined with standard treatments like radiotherapy or chemotherapy, or with small-molecule inhibitors of virus-host interactions. Here, we focus specifically on OVs engineered to encode a transgene for the tumor protein p53 (TP53). Since its discovery in 1979 11 and identification as a tumor suppressor in 1989, 12 p53 has been extensively studied for its role in suppressing tumorigenesis and explored as a promising cancer therapeutic.
However, unlike p53, p63 and p73 contain an additional Sterile Alpha Motif (SAM) domain, which plays a role in protein-protein interactions and in lipid binding. 21, 22 Contrary to p53, the tetramerization domains of p63 and p73 proteins can lead to the formation of mixed heterotetramers consisting of p63 and p73, but not p53, subunits. 23 Like p53, p63 and p73 are able to transactivate similar target genes including p21, BAX, and GADD45, as well as provoke cell cycle arrest and apoptosis through various mechanisms. 24 In addition, p63 and p73 have the ability to trigger autophagy, senescence, differentiation, immune system activation, or angiogenesis regulation. [25] [26] [27] [28] [29] A better understanding of the expression, modifications, and tumor suppressor functions of the known p53 isoforms and p63 and p73 family members is essential for the rational development of a p53-based gene therapy.
WT p53 is a key player in cancer development not only because of its normal functions as a powerful tumor suppressor, but also through its devastating roles once mutated, mostly via missense mutations (especially at hotspots V157, R158, R175, G245, R248, R249, and R273). 30 Those mutations have two major consequences: First, they can cause the loss of function of normal p53 via several mechanisms. In particular, in the heterozygous form, many mutant p53 proteins show a dominant-negative effect via heterotetramerization with WT p53, preventing its normal checkpoint functions. 31 Second, many p53 mutants acquire gain-of-function oncogenic activities, promoting cell survival, proliferation, invasion, migration, chemoresistance, tissue remodeling, chronic inflammation, as well as inactivation of p53 paralogs p63 and p73, which belong to the same p53 tumor suppressor family and are important tumor suppressors. 32, 33 Not surprisingly, tumors depleted of the WT p53 gene retain the mutant form of the protein and thus gain a selective advantage. 34 Importantly, although p53 mutations are present in approximately 50% of cancers, in almost all cases where WT p53 is retained, its tumor suppressor function is eliminated via direct binding of two main p53 binding protein groups: (1) cellular mouse double minute 2 homolog (MDM2) or transformed mouse 3T3 cell double minute 4 (MDM4: also known as MDMX), 35, 36 or (2) proteins encoded by DNA viruses such as the E6 protein of high-risk human papillomavirus (HPV). 37 Finally, mutations in the conformation-sensitive core domain of p53 induce the association of p53 with chaperone proteins such as heat shock protein 90 (Hsp90) forming a complex p53-Hsp90-MDM2 and provoking the MDM2 inhibition leading to the stabilization of p53 mutants. 38 Various pharmaceutical approaches have been developed to restore the WT function of p53 mutants (using p53 reactivation and induction of massive apoptosis [PRIMA-1], SH group-targeting compound that induces massive apoptosis [STIMA-1], CP-31398, and other compounds) or to block interactions of WT p53 with MDM2/ MDMX (using nutlin-3a, RG7112, CGM097, SAR405838, and other compounds). 28, 29, 39, 40 Each of these approaches has its limitations. For example, it is unclear whether PRIMA-1 and similar compounds effectively target all mutant p53 variants and whether the tumor suppressor functions of p63 and p73 could be negatively affected by these drugs. Further, although MDM2/MDMX antagonists may be beneficial in cancers with WT p53 and high MDM2/MDMX expression, they are unlikely to be effective in tumors with a high prevalence of p53 mutations, where Hsp90 inhibits MDM2-mediated mutant p53 degradation. 38 Moreover, because in the absence of this Hsp90 activity MDM2 is able to inactivate p53, 38, 41, 42 the use of MDM2/ MDMX antagonists in premalignant lesions may increase the number of p53 mutant forms and the risk of tumor progression. Indeed, longterm exposure to nutlin-3a promotes the emergence of p53 mutations. 29, 30, 40, 43 Many of these challenges associated with p53 could be more effectively addressed through the development of approaches allowing successful delivery and expression of the WT p53 transgene in tumor cells. Unlike the pharmaceutical approaches described above, p53 gene therapy is expected to be effective independently of the p53 tumor status. The history of p53 as a cancer gene therapeutic has been reviewed. 44 In brief, in the late 1980s and early 1990s it was known that treatment of cancer cells with WT p53 resulted in senescence 45 or apoptosis 46 depending on the cancer tested. Dr. Jack Roth (MD Anderson Cancer Center) was the first to successfully use p53 therapy in vivo in humans using replication-deficient retroviral vector-driven expression of human p53 against non-small cell lung carcinoma. 47 The focus of the p53-based cancer gene therapy field then shifted to replication-deficient adenoviral vectors because of their low risk of integration into the host genome, the ability of the vectors to inhibit growth of many malignancies in vitro, and the ability to achieve costeffective, large-scale good manufacturing practice (GMP) production. 44 Since then, many clinical trials were conducted using different p53 expression replication-deficient viral vectors (discussed below), with thousands of patients receiving the therapies without significant adverse effects. This approach also had limited success. 44 To date, no such therapeutic approach has been approved in the United States.
This review discusses the large number of preclinical studies combining the benefits of replication-competent OV therapy with p53 gene therapy in vitro and/or in vivo. First, we highlight how the expression of WT p53 transgenes improves OV therapy safety and oncoselectivity, increases oncotoxicity, and augments anti-tumor effects by promoting the stimulation of anti-cancer immune responses. We also review strategies to modify and improve p53 activities to counteract cancer cell resistance to p53 gene therapy. To facilitate comparisons, we organize OV-p53 viruses (WT or modified transgenes) (see Table 1 ) based on their modifications and the issues they address. Finally, we review preclinical and clinical studies (see Table 2 ) that utilized replication-deficient gene therapy vectors expressing a p53 transgene, with a focus on their prospective use in the context of OV therapy. [48] [49] [50] [51] [52] [53] [54] [55] [56] For example, in contrast with WT mice, p53 À/À mice were highly susceptible to vesicular stomatitis virus (VSV; a rhabdovirus) and succumbed to VSV infection. Furthermore, a 100-fold increase in VSV load was observed in the sera of p53 À/À mice compared with WT mice. 49 Based on these studies, the addition of a p53 transgene to an OV genome may attenuate the OV in normal cells.
The conditionally replicative adenovirus (CRAd) encoding p53 (SG600-p53) has been subjected to a comprehensive safety study by Su et al. 57 The CRAds are replication-competent adenoviruses that selectively replicate in tumor cells. The restriction of CRAd replication to tumor cells is generally based on a tumor-specific promoter controlling the expression of an essential early adenovirus gene or involves mutations in viral genes, 44, 45, 58, 59 allowing CRAds to replicate in tumor cells, but not in normal cells. 60 Su et al. 57 investigated SG600-p53, where the viral E1a gene has a deletion of 24 nt and is controlled by the promoter of human telomerase reverse transcriptase (hTERT), the E1b promoter is replaced by a cis-element of five copies of hypoxia regulatory element (HRE), and the p53 transgene cassette was inserted between the E1a and E1b genes. Following intravenous (i.v.) administration of increasing virus doses in mice (1-4 Â 10 11 virus particles [VP]/kg) or in cats (2-8 Â 10 10 VP/kg), no toxic effect was observed (behavioral, nervous, cardiovascular, and respiratory systems were examined). 57 Further, after the intramuscular (i.m.)
administration of a very large virus dose (2.5 Â 10 13 VP/kg), mice survived without weight loss or signs of cyanosis, hyperspasmia, inflammation, or ulceration. Whether SG600-p53 could trigger anaphylaxis in guinea pigs following several intraperitoneal (i.p.) and i.v. injections also was tested. No animals died or presented signs of anaphylaxis. Repeated i.m. injections of SG600-p53 in rats (1-10 Â 10 11 VP/kg) and in cynomolgus monkeys (5-50 Â 10 10 VP/kg) were also shown to be safe. 57 Other OVs armed with a p53 transgene were demonstrated to be safe in animals, including Newcastle disease virus (NDV; a paramyxovirus) 61 and various recombinant VSVs. 62 Toxicity studies in mice showed that after 10 systemic injections of rNDV-p53 (1 Â 10 7 PFU each), the serum from mice showed no changes in serum creatinine, aspartate transaminases, alanine transaminases, or blood urea nitrogen levels, supporting the safety of that virus. 61 However, neither the CRAd SG600-p53 57 nor rNDV-p53 61 studies investigated specific contributions of the p53 transgene to the safety of these viruses because they were not compared with control viruses. This issue was addressed in a VSV study comparing VSV-M(mut)-mp53 [an attenuated VSV-M(mut) virus encoding murine p53] against its parental virus VSV-M(mut). 62 The study showed that following i.v.
injection of 10 8 to 10 9 plaque-forming units (PFUs), 84% (6/7) of the mice treated with VSV-M(mut)-mp53 compared with 14% (1/7, one mouse died unrelated to virus-induced encephalitis) of the mice treated with VSV-M(mut) survived treatment, indicating that VSV-M(mut)-mp53 was safer than VSV-M(mut). This study utilized M(mut), a mutant matrix (M) protein gene of VSV used to improve 66 The utilization of these mutant M proteins not only improves VSV oncoselectivity, but also allows for the expression of p53 target genes in cancer cells infected with VSV-M(mut)-mp53.
Although these studies demonstrated safety of OVs bearing p53 transgenes, over-attenuation of the OVs as a result of the WT p53 activities that stimulate antiviral signaling [48] [49] [50] [51] [52] [53] [54] [55] [56] remained a concern. Indeed, such activities of virus-encoded p53 transgenes in cancer cells could reduce OV efficacy by decreasing virus oncoselectivity. To address this important concern, our recent study engineered and compared VSV recombinants either expressing WT human p53 fused to near-infrared fluorescent protein (eqFP650, herein called RFP) ("VSV-p53wt") or expressing RFP only ("VSV") for the abilities of these viruses to induce type I IFN signaling in several human pancreatic ductal adenocarcinoma (PDAC) cell lines.
67 Surprisingly, and in contrast with the expected enhancement of antiviral signaling by p53, expression of genes associated with type I IFN signaling pathway was dramatically attenuated in p53 transgene-expressing cells. For example, although a 291-fold increase in IFN-b transcripts was detected in cells infected with the VSV recombinant that does not express p53, only a 25-fold increase in IFN-b transcripts was observed in cells infected with VSV-p53wt. 67 These data suggest that OV-encoded p53 can simultaneously produce anti-cancer activities while assisting, rather than inhibiting, virus replication in cancer cells. Although the exact mechanism of this observation is unknown, our additional experiments suggested that p53 is likely to inhibit the type I IFN response via inhibition of nuclear factor kB (NF-kB), which is usually constitutively expressed in PDAC cancer cells and is crucial for early IFN-b expression and resistance to virus replication. 68 The inhibition of the NF-kB pathway by p53 via several mechanisms has been shown, including prevention of NF-kB nuclear translocation through upregulation of NF-kB inhibitor, IkBa, 69 competition between p53 and NF-kB for common transcription cofactors, 70 or direct binding of p53 to NF-kB (RelA subunit p65) to prevent its binding to DNA. 71 In addition, p53 also can decrease the IFN response through STAT1 inhibition, in particular by increasing the expression of the STAT1 inhibitor suppressor of cytokine signaling 1 (SOCS1). 72 Importantly, our study also showed that recombinant VSVs encoding the p53 transgene were not able to inhibit antiviral signaling in non-malignant human pancreatic ductal cells, which retained their resistance to viral infection. The inability of p53 to inhibit OV replication in cancer cells also was demonstrated for adenoviruses expressing p53 in vitro. 73, 74 One of these studies compared AdD24 and AdD24-p53 viruses. 74 AdD24 carries a 24-bp deletion corresponding to aa 122-129 in the CR2 domain of E1A necessary for binding to the Rb protein, and it lacks the entire E3 region, whereas AdD24-p53 also encodes a p53 transgene in place of the deleted E3 region. In vivo, AdD24-p53 demonstrated the same rate of replication in subcutaneous xenograft glioma IGRG121 in athymic nude mice compared with the parental virus AdD24. 75 Similarly, the inability of p53 to inhibit replication of AdD24-p53 was observed in IGR-NB8 and IGR-N91 neuroblastoma tumors. 76 
Improved Oncotoxicity
One of the major advantages of using p53-armed OVs is their enhanced oncotoxicity in vitro and in vivo. In this section, we focus on direct OV-mediated oncotoxicity following virus infection and replication in cancer cells, with cell death occurring independently of the activation of adaptive immunity against tumor. Such direct oncotoxicity is typically measured in vitro (where immune cells are naturally absent) or in vivo in athymic mice, typically by testing an OV against a panel of human cancer cell lines. Most studies examining the effects of WT p53 transgene expression on OV cytotoxicity have been conducted using CRAds. The original study analyzing the effect of human WT p53 on CRAd cytotoxicity was conducted using AdD24-p53. 74 The addition of the p53 transgene resulted in virus cytotoxicity in vitro in 80% of tested cancer cells from different tissues, accelerating cell death by several days and increasing the early virus progeny release. The CRAd potency was 100-fold higher when p53 was expressed, regardless of the test cell endogenous p53 status (p53-WT, p53 null, p53-R248Q, or p53-R273H). 74 The same CRAd AdD24-p53, compared with the parental AdD24, was more potent in killing malignant glioma cell lines 75 and neuroblastoma cell lines. 76 As in the previously described study, 74 the increase of viral cytotoxicity was independent of the intracellular p53 status. Interestingly, the glioma xenograft-derived short-term cultured IGRG121 (primary multiforme glioblastoma) and IGRG88 (malignant oligodendroglioma) cell lines were both sensitive to CRAds in vitro but responded differently in vivo. 75 Indeed, compared with injections of parental AdD24, intratumoral (i.t.) injections of AdD24-p53 into IGRG121 xenograft in athymic nude mice led to delayed tumor growth, tumor regression, and improved survival. 75 Tumor mass showed increased necrosis, lymphatic infiltration, and apoptosis. 75 In contrast, both AdD24-p53 and AdD24 were ineffective against IGRG88 in vivo. This study highlights certain limitations of p53-mediated OV therapy.
WT p53 transgenes also increased cytotoxicity of two other OVs, VSV and NDV. 48, 54, 61, 67 In our recent study, VSV-p53 showed enhanced killing of the pancreatic cancer cell line SUIT2 compared with VSV not expressing p53 when these viruses were tested at a low MOI. 67 rNDV-p53 encoding a p53 gene provoked stronger suppression of cell growth in HepG2 human hepatocellular carcinoma cells and improved early apoptosis by reducing mitochondrial membrane potential, compared with rNDV in vitro. 61 In vivo, after i.t. injection, rNDV-p53 suppressed tumor growth in an H22 murine hepatoma cell xenograft model in nude mice more efficiently than rNDV, An enhanced innate immune response against tumor cells was reported for AdD24-p53, which was efficient in vivo against different neuroblastoma xenografts (IGR-N91 and IGR-NB8) in athymic nude mice after i.t. injection by provoking the infiltration of inflammatory cells such as lymphocytes and macrophages into the tumor site. 76 
Modifying p53 Activities to Improve OV Therapy OVs Encoding Modified p53 Transgenes
Many strategies have been developed to increase p53 efficacy and counteract resistance of cancer cells to p53 therapy to improve OVp53 therapy. One of the most notable problems of any p53-based cancer gene therapy is the ability of many tumors to inhibit virus-encoded exogenous p53 activities by cellular proteins such as MDM2 or MDMX, 35, 36 or viral proteins such as E6 of HPV. 37 Various modifications of WT p53 have been engineered to prevent such inhibitions. For example, endogenous cellular p53 expression is controlled by a cellular E3 ubiquitin protein ligase, which regulates p53 expression through a negative feedback loop. When p53 is expressed, MDM2 binds to and ubiquitinates p53 to cause its degradation by the proteasome pathways. 65, 66, 78, 79 Such MDM2 activity can inhibit not only endogenously expressed p53, but also virus-encoded exogenous p53. MDM2 is known to be overexpressed in many cancers like lung, glioma, myeloma, chronic lymphocytic leukemia, B cell lymphoma, and osteosarcomas cancer cells. 80 In addition to MDM2, the adenoviral proteins E1b55K and E4orf6 assemble an E3 ubiquitin ligase complex together with cellular proteins Cullin 5 and Elongin B/C, and, similarly to MDM2, induce p53 degradation. 68, 69, 81, 82 Thus, cancer cells, via MDM2 overexpression or when infected by E1b-55Kd-expressing adenoviruses, develop resistance to exogenous p53, decreasing the efficacy of p53-based gene therapy. To address this issue, Sauthoff et al. 83 engineered an oncolytic adenovirus encoding a p53 transgene with amino acid (aa) 23 mutated from tryptophan to serine (W23S) (Figure 1) . Although p53 interacts with MDM2 via aa 19, 23, and 26, the W23S change was sufficient to abrogate binding between both proteins. 84 Importantly, the same mutation also prevented E1B-55Kd-mediated degradation of p53, but did not decrease the p53 capacity to transactivate its target genes such as p21, which is important for the promotion of the anti-tumor effects of p53. In addition, this mutation did not inhibit the infectivity of the oncolytic adenovirus. 83 In agreement with the improved qualities of the p53-W23S protein, the adenovirus Adp53W23S was more efficient in vitro in several tested cell lines compared with the Adp53 (encodes WT p53) and Ad-co viruses (a control adenovirus not encoding p53). However, in an A549 lung tumor xenograft tumor model, tumor size was unaffected by p53 expression. It is likely that the failure in vivo was due to a possibility that p53-W23S, although resistant to MDM2 and E1B-55Kd, remained sensitive to the activities of two other adenoviral proteins, E1b-19Kd or E1a, both known to oppose p53 functions. Indeed, E1b-19Kd is known to be an inhibitor of p53-dependent apoptosis. 72, 73, 85, 86 In addition, two cellular proteins, p300 or p400/TRAPP, are cofactors of p53 and also can be inhibited by E1a, leading to a loss of p53 function. [87] [88] [89] Whether Adp53W23S was impeded by sensitivity of p53-W23S to those adenoviral proteins should be addressed in future studies with adenovirus-based OVs.
In addition to p53-W23S, other rationally designed p53 transgenes have been used in OVs. The AdD24-p53(14/19) encodes a p53 mutant with two aa substitutions (L14Q and F19S), which results in the resistance of p53 to MDM2-mediated degradation.
76 AdD24-p53(14/19) was tested in different cancer cells known to overexpress MDM2, such as MNNG-HOS and MG-63 osteosarcoma, A2780 ovary carcinoma, MKN45 gastric adenocarcinoma, and SF763 astrocytoma cell lines. Compared with AdD24 and AdD24-p53, AdD24-p53(14/19) was 10 times more efficient in killing these cell lines, although p53(14/19) was less effective in transactivation of target genes, compared with WT p53.
Another challenge to p53-based gene therapy is the expression of p53 targeting viral oncoproteins in many cancer types, originated from previous viral infections, notably high-risk HPV-encoded E6 oncoprotein. The HPV E6 protein is known to promote cell proliferation by stimulating degradation of p53 via the formation of a trimeric complex comprising E6, p53, and the cellular ubiquitination enzyme E6-AP. [90] [91] [92] [93] Such E6-expressing tumors are expected to be highly resistant to p53-based therapy. To prevent E6-mediated p53 inactivation, Heideman et al. 94 used an oncolytic adenovirus AdCB016 encoding a mutant of murine p53 (mp53) called mp53(268N), where an aspartate residue was substituted by asparagine at the position . 94 It should be noted that the AdCB016-mp53(268N) virus, in addition to the successful expression of functional p53, exhibited preferential replication in HPV E6/E7-expressing keratinocytes compared with normal keratinocytes. This is due to two deletions in the adenoviral E1A protein, one in the CR2 domain to prevent sequestration of cellular retinoblastoma protein (pRb) from E2F by HPV E7, and another one in the CR1 domain to abolish E1A binding to p300 histone acetyl transferase (required for adenoviral replication), which can be functionally complemented by HPV E6. Therefore, AdCB016 can preferentially replicate in HPV E6/E7-expressing cells. 95 Another challenge for p53 gene therapy is the expression of endogenous p53 dominant-negative mutants in many cancer types. Mutant p53 proteins show a dominant-negative effect via heterotetramerization with WT p53, preventing its normal checkpoint functions. 31 Several approaches may be applicable to address this challenge, although most are not yet tested in the context of OV therapy. For example, Okal et al. 96 engineered a chimeric p53-CC, which evades the dominant-negative activities of endogenously expressed mutant p53. Similarly to the C terminus of WT p53, the CC domain of the Bcr protein allows for formation of antiparallel tetramers, but unlike the C terminus of WT p53, the CC domain is not a binding site for endogenous mutant p53. 96 As a result, the chimeric p53-CC protein was shown to evade endogenous dominant-negative p53 and restore p53 activity better than WT p53 in vitro. 96 In our work, we adopted this p53 design to generate VSV expressing either WT p53 or p53-CC. 67 The VSV-directed p53-CC was tested in several pancreatic cancer cell lines and demonstrated better transactivation activities compared with VSV-directed WT p53. Although both WT p53 and p53-CC inhibited type I IFN response in cancer cells, but not normal cells (likely via blocking the NF-kB pathway), the p53-CC transgene did so more effectively. 67 Finally, an interesting approach was used by Takenobu et al. 97 to increase the efficacy of the exogenous p53 by fusing it to a cell-penetrating peptide (CPP), 11R (11 polyarginine peptide). CPPs are used in gene therapy applications to facilitate cellular intake/uptake of various molecules (from small molecules and large fragments of DNA or even whole proteins) through endocytosis. 98 The engineered adenovirus virus, SG7605-11R-p53, tested in gallbladder cancer cell lines in vitro and against EH-GB1 xenografts in vivo in mice, demonstrated that infection with p53-11R fusion improved the anti-tumor effect and prolonged survival, compared with control viruses. 99 The mechanisms of this improvement are unclear. It is possible that after successful replication of SG7605-11R-p53 in infected cells, a large amount of p53-11R was produced, released, and, because of 11R, was able to enter uninfected cells to improve the bystander effect.
Combination of OV-p53 Transgene with Radiotherapy
Because p53 has been shown to enhance the effects of radiotherapy (radiosensitization), [100] [101] [102] [103] [104] [105] Idema et al. 106 tested the combination of OVs with radiotherapy against glioma cancer cells in vitro and in vivo. Either AdD24 or AdD24-p53 and radiotherapy increased anti-tumor efficacy compared with each single treatment, both in vitro and in vivo. In vitro, AdD24-p53 was more effective against glioma cells than the control AdD24, and the combination of radiotherapy with AdD24-p53 caused an increase in the percentage of apoptotic cells. In contrast, although OV and radiotherapy combinations increased anti-tumor efficacy compared with each single treatment in vivo, no differences between viruses could be seen. Although this study highlights that AdD24 or AdD24-p53 combined with radiotherapy can eradicate tumors, which would otherwise escape OV monotherapy, the authors concluded that this additive effect was not due to the p53 transgene expression. 106 
Lessons from Preclinical and Clinical Studies Using ReplicationDeficient p53 Gene Therapy Vectors Expressing Other p53 Family Members
Although several approaches to overcome the exogenous p53 inactivation in tumors were described above, another approach uses other members of the TP53 gene family, p63 (TP63/p51/p73L/p40) or p73 (TP73), each presenting unique advantages. For example, p63 and p73 can arrest the cell cycle in G1 phase via upregulation of p21 and p57/ Kip2 transcripts. Moreover, p63 and p73 can trigger intrinsic apoptosis via the induction of Bax and PUMA proteins, leading to BAX translocation to the mitochondria, cytochrome c release, and a decrease in the mitochondrial membrane potential. [107] [108] [109] Importantly, p73 and p63 can also induce cell death in a p53-independent manner through the upregulation of scotin, a trans-membrane protein that causes endoplasmic reticulum (ER) stress. 98, 99, 109, 110 On the other hand, p63 and p73 also act on the extrinsic apoptosis pathway by inducing the expression of death receptors like TRAIL-R1/R2, TNF-R1, and FAS. 96, 98, 100, 107, 109, 111 Thus, p63 or p73 therapy could complement the apoptosis triggered by the endogenous p53 or, in the case of p53-deficient cancer cells, allow the induction of apoptosis in a p53-independent manner. Kunisaki et al. 112 showed that the overexpression of p53 and p63 by adenoviral transduction in EBC1 lung cancer cells led not only to an improved suppression of cell growth in vitro, but also in vivo via apoptosis induction. Unlike p53 and p73, p63 interacts very weakly with MDM2 and has strong anti-tumor activities even in cancer cells overexpressing MDM2. 41 Also, the oncoproteins E6 and E1B-55Kd are not able to inactivate the p73 transgene encoded by an adenoviral vector, which is still active against cervical cancer cells overexpressing HPV E6. [113] [114] [115] Similarly, Das et al. [116] [117] [118] demonstrated that a replication-deficient adenovirus (Ad-p73) bearing a TP73 transgene showed stronger growth inhibition of HPV 16 E6-expressing cells, but also other human cancer cells via a cell cycle G1 phase arrest, and increased apoptosis, with an increased p21 expression noted after infection by Ad-p73.
In contrast with p53, which is often mutated and inactivated in human cancers, only a few mutations have been reported for p63 or 20 For example, the N-terminally truncated p73a (DNp73a, lacks its transactivation domain) is overexpressed in some cancers (e.g., breast, lung, neuroblastoma, vulval, and ovarian), and this mutant is associated with a poor prognosis in patients. Indeed, DNp73a cellular expression impairs the abilities of p53 and p73 to transactivate target genes, which leads to apoptosis resistance. This truncated form of the p73 protein has been assessed in immunotherapy to overcome immune tolerance and to develop an anti-tumor response. Hu et al. 119 showed that immature dendritic cells transduced by a DNp73a recombinant adenovirus presented the tumor-associated antigen DNp73a to lymphocytes, which in vitro provoked a specific immune cytotoxic T lymphocyte (CTL) response against A549, K-562, and MCF7 cancer cells expressing high levels of DNp73a. Moreover, metastatic melanoma cells typically overexpress the p73 isoform DTA-p73, which is associated with impaired apoptosis and resistance of chemotherapy. 120 To overcome the DTA-p73 effects, Tuve et al. 121 infected melanoma cells with an adenovirus bearing the isoform TA-p73b gene capable of producing a transcriptionally active form of p73, which evaded the effects of the endogenous DTA-p73 effects in vitro and in vivo, and increased melanoma chemosensitivity through the induction of p21.
Combining p53-Based Gene Therapy with Histone Deacetylase Inhibitors
Histone deacetylase inhibitors (HDACi) are classified as chemotherapeutic agents showing high efficiency against various cancers. For example, HDACi could enhance gene therapy with transgenes encoding p53 family members. Generally, HDACi induce hyperacetylation of nucleosome core histones, which results in transcriptional activation and expression of genes that may inhibit tumor cell growth. 122 Moreover, HDACi have been shown to induce acetylation of non-histone proteins, including p53, 123 thus inducing anti-cancer activity in a histone-independent manner. Sasaki et al. 124 investigated the combination treatment of HDACi FK228 (depsipeptide FR901228) with Ad-p53, Ad-p63, or Ad-p73 and determined that FK228 provoked hyperacetylation of the Ad-p53-encoded exogenous p53 protein. Acetylation of p53 was previously shown to be important for activation of p53-targeted gene expression and apoptosis induction. 125 In addition, the same study showed that FK228 treatment increased the expression level of the exogenous p53 in MKN45 cells. The increases in p63 and p73 expression levels were also detected in the presence of FK228 for Ad-63 and Ad-73 vectors, respectively. Pretreatment of MKN45 and SW480 cells with FK228 also greatly enhanced apoptosis and sensitized the cells to adenoviral infection. The increase in apoptosis resulted from a combination of FK228 with a recombinant adenovirus, which triggered BAX translocation from cytosol to the mitochondria. FK228 also increased expression levels of the coxsackievirus adenovirus receptor (CAR, often downregulated in cancer cells), leading to an enhanced infection. Furthermore, FK228 improved the effects of p53 and p63 transgenes (Ad-p73 was not tested) in vivo in MKN45 xenografts. 124 Another HDACi, suberoylanilide hydroxamic acid (SAHA), also was shown to ameliorate adenovirus infection by increasing expression of CAR. 126 Moreover, SAHA complemented the effects of adenoviral vectors bearing a p63 or a p73 transgene to kill head and neck squamous cell carcinoma (HNSCC) cell lines via apoptosis by an enhanced expression of p21 and cleaved-Poly(ADP-Ribose) Polymerase 1. In addition, the effect of SAHA was specific to cancer cells, showing no toxicity in normal fibroblasts.
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The approaches using HDACi described here have been tested mainly in the context of gene therapy using replication-deficient viral vectors. However, one study tested a replication-competent OV to genetically downregulate HDAC. In this study, Schipper et al. 127 made an oncolytic adenovirus OV.shHDAC1.p73 encoding both the p73 transgene and small hairpin RNA (shRNA) against histone deacetylase 1 (shHDAC1), and they tested this virus in vitro and in vivo. The study showed that the presence of shHDAC1 and p73 enhances cell cytotoxicity by promoting apoptosis via caspase-3 cleavage and triggering autophagy in infected cells, which led to increased production of virus progeny in vitro in SK-Mel-147 and SK-Mel-103 cells. In vivo, i.t. injection of OV.shHDAC1.p73 (10 8 PFU) into subcutaneous tumors established from human SK-Mel-147 melanoma cells in nude mice showed a complete tumor regression within 17 days after treatment and showed an enhanced anti-tumor efficacy compared with the control viruses. The treatment with OV.shHDAC1.p73 also prolonged mouse survival, and no recurrence of tumors was observed within 16 weeks. 127 
Lessons from Clinical Trials Using Replication-Deficient p53 Vectors
Because numerous studies demonstrated an improved anti-tumor efficacy of viral vectors encoding a p53 transgene in preclinical models, different clinical trials were performed in cancer patients (summarized in Table 2 ). To the best of our knowledge, all clinical trials used replication-deficient viral vectors. The first phase I clinical trial was conducted with the retroviral vector (ITRp53A) against lung cancer. The retrovirus encoding WT p53 was injected i.t. (5 Â 10 7 CFU) and was safe and well tolerated by patients. The p53 transgene expression directed by the retroviral vector was detectable in tumors and resulted in increased apoptosis. 47 Nine patients were treated: three showed tumor growth stabilization and three showed minor tumor regression. Although these results seem promising, the safety limitations of the retroviral vector system shifted the focus of p53-based gene therapy to other vectors. Most of the subsequent trials used adenoviral vectors SCH58500 or INGN201 containing a WT p53 transgene. [128] [129] [130] [131] [132] [133] [134] [135] [136] [137] Both SCH58500 (Schering-Plough) and INGN201 (also known as Advexin; Introgen Therapeutics) contain a WT p53 expression cassette in place of the Ad E1 region, with WT p53 gene under the control of the human cytomegalovirus promoter. These vectors were tested against various tumors such as lung, glioma, neurinoma, breast, pancreas, colorectal, bladder, ovarian, head and neck, thyroid, liver, skin, or liposarcoma and were delivered as a single agent or in combination with chemotherapy and/or radiotherapy ( Table 2) . Most of those clinical trials were phase I or II, but two phase IV trials are ongoing with the adenoviral vector rAd-p53 against oralmaxillofacial (NCT00902083) and thyroid (NCT00902122) tumors. 133 and bronchoalveolar lavage (2 Â 10 9 to 2 Â 10 12 VPs), 138 respectively. Finally, a recent clinical trial used percutaneous injections against hepatocellular carcinoma (NCT00003147). In most cases, the rAd-p53 vector was safe, well tolerated by patients, and lacked severe toxicities. However, some transient side effects like fever, leucopenia, nausea, and an increase of bilirubin were observed. Concerning the anti-tumor effects, the therapeutic vector reached the tumor site despite the presence of adenoviral neutralizing antibodies and promoted p53 transgene expression detectable in the nuclei of cancer cells, likely leading to increased apoptosis. Consequently, the majority of patients who received OV therapy displayed a regression of tumor mass or a transient stabilization of their disease.
Another strategy tested in clinical trials was to vaccinate cancer patients with dendritic cells isolated from the same patients and infected ex vivo by a recombinant virus encoding WT p53. 139 The goal was to stimulate the adaptive immune system, specifically the CD8 + T lymphocytes, to provoke a specific anti-tumor response against tumor cells overexpressing high levels of p53. Indeed, unlike WT p53, which has a short half-life and is weakly expressed in normal cells, mutant p53 has a prolonged half-life and is overexpressed in cancer cells. Many studies show that such immunization of animals with WT p53 (using viral or non-viral delivery) results in a substantial CTL response against tumor cells not only expressing WT p53, but also mutant p53 genes, with no signs of autoimmune reactions to normal cells. [140] [141] [142] [143] [144] [145] [146] Translating this approach to the clinic, we used dendritic cells infected by rAd-p53 in a phase I trial against small cell lung cancer (SCLC) via intradermal injections. 139 In this trial, 57.1% of patients developed a p53-specific CTL response, and one patient showed a clinical response (a 60% decrease in the size of all of her measurable lesions) after vaccination. In addition, similar clinical trials (phase I/II) were recently performed on SCLC by combining vaccination of dendritic cells infected by rAd-p53 with T lymphocytes (NCT00776295) or with chemotherapy like carboplatin or etoposide (NCT00049218) in an attempt to improve the anti-tumor response.
The p53 vaccination strategy also was used in a phase I trial with a direct administration of a Modified Vaccinia Ankara virus (p53-MVA). p53-MVA is an attenuated vaccine strain of a poxvirus encoding WT p53. 147 In this trial (NCT01191684), 1 Â 10 8 to 5.6 Â 10 8 PFU was administrated subcutaneously in 12 patients with refractory gastrointestinal cancers. The virus was well tolerated with no strong side effects, and a high CTL cell response was observed against tumor cells expressing p53. However, this effect was transient, suggesting that p53-MVA requires combination with immunomodulatory agents to deliver clinical benefit. 147 Currently, two other phase I trials are planned for patients having solid tumors (NCT02432963) and recurrent ovarian cancers (NCT02275039) by combining p53-MVA vaccination and chemotherapy such as gemcitabine or pembrolizumab.
Conclusions
Important advances have been made in combining OV therapy with p53 gene therapy. Despite some interesting observations in replication-deficient viral vector clinical trials, the therapeutic effects of p53 gene therapy have been limited. Some of the failures may be attributed to the nature of gene therapy (use of replication-deficient viral vectors, biology of adenovirus-based vectors), rather than limitations of p53. By design, replication-deficient viral vectors are unable to spread within the tumor, and they exert their effects in proximity of the injection site. With regard to the adenoviruses (replication-deficient vectors or replication-competent OVs), efficacy is often limited by virus capture by the reticuloendothelial system (RES), notably by Kupffer cells (KCs) in the liver [148] [149] [150] [151] [152] and by pre-existing serum antibodies. 143, 144, 153, 154 Also, adenovirus infection can be restricted by the low expression of the CAR in many tumors. [155] [156] [157] [158] In our opinion, replicating OV-p53 viruses based on other viruses (or adenoviruses with a modified tropism) could be more relevant in future clinical trials, because they may spread within the tumors amplifying p53 expression and increasing oncolysis. Moreover, replicating OVs could improve the anti-tumor response by the lysis of tumor cells to allow the release of numerous anti-tumor antigens into the tumor microenvironment. These antigens could be processed and potentially lead to sustainable adaptive immune responses. Finally, during in vivo treatment, OV-p53 could infect dendritic and T cells and could stimulate an adaptive immune response against cancer cells overexpressing mutant p53, essentially vaccinating patients. Thus, OV-p53 therapy can simultaneously achieve direct oncolysis and anti-tumor immunity (against several tumor-specific antigens, including mutant p53).
We think that several approaches with p53 transgenes successfully tested with replication-deficient vectors could be tested in the context of OV therapy. Most of the previous studies tested OVs that encode a major variant of the WT p53. As mentioned above, WT p53 has at least 12 isoforms, and they could be compared for the anti-tumor effects as OV-encoded transgenes. Moreover, WT p53 variant sequences could be used to generate p53 with posttranslational modifications that may increase efficacy. We envision a rationally designed p53 with a modified DNA binding domain to target and turn off cancer-specific gene regulatory sequences, like vi-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), such that the therapy may slow cancer growth and spread. Additionally, p53 fusions with other proteins or protein domains could be tested.
Although most of the studies used human p53, comparison with animal orthologs likely would yield additional knowledge. Also, further investigations of OVs encoding p63 and p73 will improve OV-p53 therapy, and it will be useful to test whether their co-expression from the same OV could provide an additive therapeutic effect. 159 recently showed that the activity of p53 fused to a light-inducible nuclear export system (LEXY; based on a single, genetically encoded tag) can be controlled by light. This and other p53 variants could be tested in the context of OV in a variety of available in vitro and in vivo systems.
We anticipate that more studies will be conducted combining OV-p53 viruses with chemotherapy or small-molecule inhibitors targeting endogenously expressed mutant p53 and/or MDM2/4. Other therapeutic strategies could be developed to promote mutant p53 degradation. Indeed, we have already highlighted above that p53 mutants can be stabilized in cells notably via the formation of MDM2-Hsp90-p53 complex leading to MDM2 inhibition. However, to be functional this complex requires an interaction with HDAC6. 160 This is why an OV bearing a p53 transgene and a shRNA sequence against HDAC6 could be useful to impair the complex MDM2-Hsp90-p53 formation and promote the degradation of p53 mutants by MDM2 or by other chaperone-associated E3 ubiquitin ligase such as CHIP. 161, 162 OV-p53 also could be combined with other molecules capable of blocking the pathways regulated by mutant p53. For example, mutant p53 was shown to be responsible for abnormal architecture of breast tumors, and the use of statins demonstrated that this abnormality was a result of mutant p53-induced upregulation of the mevalonate (cholesterol synthesis) pathway in the tumor cells. 163 This mechanism may explain why statins, which are well established in the clinic to treat hypercholesterolemia, have been shown to exhibit anti-cancer activities in several studies. 33 Also, some studies demonstrated that p53 mutants can stimulate tumor growth via activation of several kinases, including epidermal growth factor receptor, a mesenchymal-epithelial transition kinase, as well as a mitogen-activated protein kinase. [164] [165] [166] [167] Therefore, the use of statins or the inhibitors of these kinases in combination with OV encoding p53 could provide additional benefits.
Although speculative, the ideas mentioned above highlight the vast expanse of preclinical research yet to be explored. What is certain, however, is that the marriage of OVs and p53-based therapies is progressing and will lead to important clinical successes.
